S. Korea’s Daewoong, Dong A, Yuhan, Others Brace For U.S. FTA Impact
This article was originally published in PharmAsia News
South Korea’s pharmaceutical industry is bracing for more competition and lower prices for its products as a free-trade agreement with the U.S. becomes operable March 15, triggering the April 1 changes.
You may also be interested in...
COVID-19 has pushed the entire health care system to adopt new technologies and new solutions for conducting clinical research and delivering care to patients. An expert panel hosted by the Galien Foundation provided a meditation on what the biopharma industry has learned so far, and how to use the urgency created by COVID-19 to lock-in technological acceleration while maintaining what FDA’s Amy Abernethy called “responsible progress.”
Zydus Cadila has clocked up two tentative and four final abbreviated new drug application approvals in a short amount of time, including for Boehringer Ingelheim’s Jentadueto and the discontinued verapamil hydrochloride for injection.
Pierre Bourdage, global head of biopharmaceuticals at Sandoz, has hit back at false statements and misleading claims around biosimilars that persist despite mounting evidence to the contrary.